OC-0481: Late toxicity and cosmesis after APBI with brachytherapy vs WBI: 5-year results of a phase III trial  by Polgár, C. et al.
S230                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
severity of the late complications were not different between 
the experimental group and the control group, p=0.54; the 
overall toxicity rate being respectively 20% vs. 21% and for 
grade III+ complications 9% vs. 6%. 
 
Conclusion: The trial showed no difference in local efficacy 
between preoperative 5x5 Gy with consolidation 
chemotherapy and standard preoperative chemoradiation. 
Lower acute toxicity, lower cost, convenience and a trend 
towards improved overall survival favour 5x5 Gy with 
consolidation chemotherapy. 
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Purpose or Objective: The aim of the ACCORD 12 trial was to 
compare two different regimens of neoadjuvant 
chemoradiotherapy (nCRT). No significant difference has 
been found in main end point (pCR rate) . At 3 years there 
was no significant difference for local control and survival. 
We report the 5 years outcome. 
 
Material and Methods: Between 11/2005- 07/2008, 598 pts 
randomized. Inclusion criteria: adenocarcinoma , distal- 
middle rectum, T3-4, anterior-distal T2 staged using MRI 
and/or endorectal US. Treatment : CAP 45 : radiotherapy 
(RT) 45 Gy/25 fr/5 weeks with concurrent capecitabine (800 
mg/m2 BID) vs CAPOX 50 : RT 50 Gy/25 fr/5 weeeks with 
Capecitabine (same) and weekly oxaliplatin (50 mg/m2). A 
TME surgery was performed after 6 weeks interval. Adjuvant 
chemotherapy was left to each institution. 
 
Results: Median follow-up time was 60 months with 299 pts in 
each group. In intent to treat analysis main results are shown 
in table. In 31 pts T4 confounded the local relapse rate was 
11.3%[3.8-31.5].A clinical CR in 24 pts was associated with 
81% DFS (p<0.0001) and Sphincter saving or organ 
preservation in 23. Adjuvant chemotherapy given in 253 pts. 
 
Endpoint CAP 45 299 pts 
CAPOX 50 
299 pts p(log rank) 
HR 
CI 95% 
Loc. Rec. 5y 8.8% 7.8% 0.78% 0.92 [0.51-1.66] 
Dist. Met. 5y 30% 28% 0.48% 0.89 [0.77-1.15] 
DFS 5y 60.4% 64.7% 0.25% 0.86 [0.66-1.11] 
Overall Surv. 5y 76.4% 81.9% 0.06% 0.71 [0.50-1.01] 
Bowel function (1-7) 5.2 4.9 NS  
 
Conclusion: At 5 years there was no significant difference for 
local recurrence, distant metastases, survival and bowel 
function rates. Both CAP 45 and CAP 50 regimens are feasible 
and provide acceptable local control rate. More prognostic 
factors will be available at time of meeting and may generate 
hypothesis to further improve local control in locally 
advanced T3 or T4, achieve organ preservation in some T2 or 
early T3 and reduce toxicity in pts > 75 y old. Gerard Jp et 
al. J Clin Oncol. 2012 Dec 20;30(36):4558-65 
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Purpose or Objective: The 5-year local control and survival 
results of the GEC-ESTRO multicentric accelerated partial 
breast irradiation (APBI) trial have been reported recently. In 
this analysis we report the 5-year late toxicity and cosmetic 
results of patients treated with APBI using interstitial 
brachytherapy (iBT) compared to those who underwent 
standard whole breast irradiation (WBI) with a tumour bed 
boost. 
 
Material and Methods: Between April 2004 and July 2009, 
1184 patients aged ≥40 years with stage 0, I and IIA breast 
cancer who underwent breast conserving surgery (BCS) were 
randomly assigned to receive either 50 Gy WBI with tumour 
bed boost of 10 Gy or APBI using HDR/PDR iBT. Among these, 
5-year follow-up records on late toxicities and cosmetic 
results were available at 969 patients (82%). Five-year 
prevalences of toxicities graded by the RTOG/EORTC late 
radiation morbidity scoring scheme were compared using the 
Fisher’s exact test. The cosmetic results were scored by the 
patients and treating radiation oncologists using the four-
scale (excellent-good-fair-poor) Harvard criteria. The trial is 
registered with ClinicalTrials.gov, NCT00402519. 
 
Results: There were no grade 4 toxicities. The cumulative 
incidence of grade (G) 2-3 late skin toxicity at 5 years was 
5.7% in the WBI group versus 3.2% in the APBI group (p=0.08), 
difference: -2.4% (95% CI: -5 – 0.2%). Concerning G2-3 late 
subcutaneous tissue side effects at 5 years the cumulative 
risk was 6.3% in the WBI group versus 7.6% in the APBI group 
(p=0.53), difference: 1.3% (95% CI: -1.9 – 4.5%). The 
cumulative incidence of severe (G3) fibrosis at 5 years was 
0.2% in the WBI group and 0% in the APBI group (p=0.46), 
difference: -0.2% (95% CI: -0.6 – 0.2%). The cumulative 
incidence of G2-3 breast pain was low in both arms (3.2% 
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after WBI; 1.4% after APBI; p=0.04) difference: -2% (95% CI: 
-3.9 – -0.1%). The rate of excellent/good cosmetic results 
judged by the patients was 87.2% versus 90.4% (p=0.06) in the 
WBI and APBI group, and 86.7% versus 88.2% (p=0.07) scored 
by the physicians. 
 
Conclusion: The 5-year toxicity profile and cosmetic results 
are similar at patients treated with BCS followed by either 
APBI using iBT or conventional WBI with tumour bed boost. A 
non-significant trend towards less late skin side effects and 
better cosmetic results has been observed in the APBI arm. 
 
Award Lecture: K. Breur Award Lecture  
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Traditional delivery of radiotherapy uses daily fractions of 
1.8-2Gy building up to a therapeutic dose over 6 to 8 weeks 
of treatment. This reflects application of the fundamental 
principles of radiobiology in which repair, repopulation, 
reoxygenation and redistribution in the cell cycle are 
considered important in defining the response of tumour and 
normal tissue. However the relevance of this approach in an 
era of more precise image guided dose delivery where the 
exposure of normal tissue is minimised and high individual 
doses can be delivered must be questioned. There are two 
scenarios in which single dose radiotherapy has been 
evaluated and found to be highly effective. The first is in the 
extensive work which has been undertaken over several 
decades to establish the role of single dose palliative 
radiotherapy. The best example of this is in the management 
of metastatic bone pain where single dose radiotherapy is 
considered the standard of care but other palliative scenarios 
in non-small cell lung cancer, oesophageal cancer, rectal, 
bladder and prostate cancer are also relevant to this 
approach. The second scenario is that of curative treatment 
for localised prostate cancer using high dose rate 
brachytherapy (HDRBT). Dose escalation using HDRBT is well 
established as an effective therapy in prostate cancer and 
there is now a substantial database of large published series 
using HDRBT alone demonstrating high biochemical control 
rates. It is now feasible to deliver single dose radical 
radiotherapy using HDR BT with low toxicity and high disease 
control rates challenging the conventional and modest 
hypofractionation schedules used with external beam. The 
relevance of conventional fractionation can now be 
challenged in the era of modern image guided radiation 
delivery for both palliative and radical treatment. A 
sufficiently high dose delivered accurately to the target 
volume is all that is required. 
 
 
Joint Symposium: ESTRO-ASTRO: In room adaptive imaging 
with a focus on MRI  
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The MRI linac originates from the desire to bring sight to the 
radiation oncologist. So to offer truly simultaneous soft-tissue 
visualization during radiation delivery. In UMC Utrecht, in 
collaboration with Elekta and Philips, a hybrid 1.5 T MRI 
radiotherapy system has been developed to facilitate this. 
Later also other systems emerged; in the Cross Cancer 
Institute in Edmonton a rotating 0.5 T MRI linac has been 
developed and the Viewray company has launched a 0.3 T 
Cobalt 60 system into the clinic. The systems will be briefly 
presented.  
The common ground of the systems is the soft-tissue 
guidance. As will be shown, MRI offers a wealth of contrasts 
for anatomical and physiological information but also motion 
data. Exploiting these data for treatment guidance and 
treatment adaptation requires a new workflow with more on-
line decisions, such as contouring, plan adaptation or full re-
planning to initialize the treatment. Moreover, the 
continuous anatomical imaging during radiation delivery 
enables new direct anatomical triggers for gating and 
tracking, but equally important, this imaging can be used for 
dose reconstruction while accounting for intra-fraction 
motion. The latter is a valuable input for dose response 
assessment and can also be used for quality assurance (QA) 
purposes. 
The QA for these systems need to be revisited, not only 
because of the new on-line plan adaptations but also due to 
the fact that the dose is delivered in the presence of a 
(perpendicular or parallel) magnetic field. This will alter the 
dose distribution which needs to be verified. Also the 
radiation detectors are potentially affected and their 
performance need to be validated (and corrected if 
necessary) for use in the presence of a magnetic field. This 
implies new machine QA , patient QA and workflow QA 
procedures. 
The promise of hybrid MRI linac technology is to enable real-
time plan adaptations in order to maximize the dose to the 
target while continuously minimizing the dose to the 
surrounding organs at risk. The efforts to move from pre-
treatment planning to once daily (on-line) plan adaptation 
and ultimately to real-time plan adaptations will be 
presented. 
In conclusion, the technology of hybrid MRI radiotherapy 
systems is there while the full clinical value needs to be 
established. This is an exciting new clinical arena and at the 
same time poses new challenges for on-line and ultimately 
real-time, adaptive radiotherapy. 
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Purpose: We report on the first two years of clinical 
operation of the first magnetic-resonance imaging-guided 
radiation therapy (MR-IGRT) program, experiences with 
patient treatments, and implications for future 
developmental and clinical work. We previously reported on 
initial clinical implementation of this system. = The purpose 
of this work is to analyze clinical practicality of MR-IGRT and 
implementation of online adaptive RT.  
 
Methods and Materials: The MR-IGRT system consists of a 
split 0.35T MR scanner straddling three 60Co heads mounted 
on a ring gantry, each head equipped with independent 
doubly-focused multileaf collimators. The MR and RT systems 
share a common isocenter, enabling simultaneous and 
continuous MR imaging during RT delivery. The system is also 
capable of online plan adaptation where patients can be 
imaged, planned, verified, and treated all in a single 
treatment session. To assess the clinical practicality of the 
system, makeup of treated cancer sites, distribution of 
available treatment techniques, total number of patients, 
maximum number of patients treated daily, and the 
utilization of advanced treatment techniques were 
evaluated. The system was clinically implemented in January 
of 2014 and data was collected over a 24 month consecutive 
period. The adaptive feature was clinically implemented in 
September of 2014.  
 
Results: During the initial 2 years of the operation, more 
than 20 cancer sites in 263 patients were treated. The 
maximum number of daily treatments was 18. Top 3 treated 
cancer sites were breast, lung, and bladder with 22%, 13%, 
and 9% of the total treatments, respectively. The utilization 
